Oct. 20, 2025 / PRZen / PARIS — In a challenging economic climate where Green IT investments have dropped by 19% in first half of 2025, a new player is redefining how international expansion works. GlexScale launches today with a straightforward conviction: the technologies that can help preserve the planet deserve to scale safer, faster, and cheaper. Getting there requires more than traditional consulting.
Unlike conventional advisory firms that stop at strategy, GlexScale integrates three critical pillars into one approach: market intelligence to decode European opportunities, go-to-market strategy tailored to local realities, and hands-on execution to turn plans into results. This end-to-end methodology eliminates the gaps that typically derail international expansion, where insights don’t inform strategy and strategy never translates into action.
A team forged in global expansion
Founded by Sylvain Mogade (CEO), Anne-Sophie Frossard (CMO), and Cyril Servissolle (COO), GlexScale draws on decades of frontline experience helping global tech companies crack European and Middle Eastern markets. Their integrated model is built on a simple observation: most market entry failures aren’t due to poor products. They’re due to fragmented execution.
“After more than 20 years building channel ecosystems for global tech leaders like Microsoft, AWS, Cisco, HCL, NTT, and WWT, one pattern kept repeating,” explains Sylvain Mogade. “Companies would get brilliant market research, solid GTM plans, and motivated partners, but these pieces rarely worked together. The intelligence didn’t shape the strategy. The strategy didn’t guide execution. And execution happened in a vacuum. For sustainable startups operating in a shrinking funding environment, that fragmentation is fatal. GlexScale exists to close those gaps by bringing the operational discipline of enterprise tech to companies that can’t afford to waste a single quarter of momentum.”
Despite the funding slowdown, the sustainability technology market is expected to exceed €500 billion globally by 2030, with the European GreenTech SaaS segment alone representing over €60 billion of that opportunity. Yet 70% of startups still face major roadblocks when expanding across Europe, from fragmented markets and cultural nuances to limited partner visibility.
“The slowdown in Green IT investment shouldn’t mean slowing down innovation,” adds Anne-Sophie Frossard. “Now is precisely the time to help technologies that make a difference cross borders, not with theory but with pragmatic execution.”
Three pathways, one integrated methodology
GlexScale’s launch offer includes three progressive programs: Explorer, Accelerator, and Visionary. Each is designed to meet companies at their stage of international readiness. Whether clarifying market opportunity, building a full go-to-market engine, or orchestrating multi-market expansion, every program follows the same core methodology: intelligence informs strategy, strategy drives execution, and execution delivers measurable market traction.
As part of its pilot phase, GlexScale is introducing a transparent milestone-based billing approach: pay only as each expansion phase is delivered.
Each critical milestone, from market intelligence reports that identify where to play to go-to-market strategies that define how to win to execution support including partner mapping and recruitment, is billed only upon completion. This phased investment model gives early clients full visibility into progress, flexibility to adjust course, and confidence that their expansion budget is tied directly to tangible outcomes.
For sustainable startups navigating tighter funding cycles, this isn’t just about payment terms. It’s about de-risking international growth entirely.
“This isn’t just business,” concludes Sylvain Mogade. “It’s a personal mission. After decades helping others scale, I wanted to use that experience to help impactful innovation grow and, in our own way, contribute to a future we can be proud of.”
About us:GlexScale unites market intelligence, GTM strategy, and execution in one revenue-focused model for SaaS companies expanding to EMEA. For more information : https://www.glexscale.com/
The Softwood Lumber Board marks National Forest Products Week by showcasing ongoing innovation in sustainable building in partnership with the Forest Service.
OREGON CITY, OREGON / ACCESS Newswire / October 20, 2025 / As the nation observes National Forest Products Week, the Softwood Lumber Board (SLB) and the USDA Forest Service are celebrating more than a decade of successful partnership that has advanced sustainable building solutions and expanded markets for softwood lumber.
The organizations first formalized their collaboration through a memorandum of understanding (MOU) in 2015, followed by an expanded agreement in 2021 aimed at growing demand for wood products. Since 2015, the SLB and Forest Service have jointly invested nearly $100 million in programs and competitions that position lumber as a sustainable and innovative building material.
These initiatives have launched city-based accelerators in Boston, New York, and Georgia; supported national design competitions showcasing lumber’s potential in schools, housing, and community infrastructure; and driven measurable growth in softwood lumber’s market share.
“This partnership is unlocking innovation across the building sector,” said Cees de Jager, President and CEO of the SLB. “Our work with the Forest Service shows that by combining resources and expertise, we can reduce barriers to low-carbon wood construction and ensure lumber continues to meet the nation’s needs for sustainable, resilient, and cost-effective housing and buildings.”
Through co-funded initiatives within WoodWorks and Think Wood, the collaboration is equipping design teams, developers, contractors, and communities with the tools and knowledge to design and construct wood buildings with confidence. These programs also support resilient forests and rural economies, underscoring the wide-reaching benefits of public-private collaboration.
Looking ahead, this joint commitment will play a central role in achieving the SLB’s strategic goal of generating 2.9 billion board feet in new annual lumber demand by 2035-ensuring lumber continues to grow its place in key markets while delivering lasting value for the industry, communities, and the environment.
“We’re proud to partner with the Softwood Lumber Board to advance the essential connections between forest management and markets,” said John Crockett, Deputy Chief for State, Private, and Tribal Forestry and the National Forest System at the Forest Service. “These efforts don’t just grow markets. They open a way to healthier forests, stronger communities, and a more sustainable future. The Softwood Lumber Board plays a vital role in these efforts, and I applaud the industry’s foresight and steady commitment. I look forward to building on this strong foundation and the impact that we can achieve in the years ahead.”
Visit softwoodlumberboard.org to learn more about the SLB’s past and current collaborations with the Forest Service.
About the Softwood Lumber Board
The Softwood Lumber Board (SLB) is an industry-funded initiative established to promote the benefits and uses of softwood lumber products in outdoor, residential, and non-residential construction. The SLB invests in strategic programs and initiatives that drive demand and grow markets for softwood lumber products in the United States.
About the Forest Service
Established in 1905, the Forest Service, an agency of the U.S. Department of Agriculture, is the nation’s foremost federal forestry organization. The agency is a world leader in forest research, providing leadership in the sustainable management, conservation, use, and stewardship of natural and cultural resources on national forests and grasslands in the United States.
Dedicated Forest Service employees manage the National Forest System, which consists of 154 national forests and 20 national grasslands covering 193 million acres in 43 states, the Virgin Islands, and Puerto Rico. The agency’s renowned fire management organization provides critical expertise in making communities and infrastructure safer. Moreover, the agency helps communities; state, local, and tribal governments; forest industries; and private forest landowners improve conditions in both urban and rural areas. In total, the Forest Service helps to steward about 900 million forested acres in the U.S., including 130 million acres in urban areas, which most Americans now call home.
First and only Berachain (“BERA”) digital asset treasury backed by the Berachain Foundation
Financing led by institutional and crypto-native investors including Polychain Capital with participation from several other prominent investors, including Blockchain.com, Kraken, North Rock Digital, CitizenX, dao5 and more.
Berachain is a Layer 1 blockchain pioneering Proof of Liquidity – a mechanism designed to accelerate the growth of onchain businesses, while capturing their value through the BERA token
The Company’s Berachain Treasury Strategy, BeraStrategy, will be led, upon completion of the Transaction, by Ben Isenberg, who will be appointed Chief Investment Officer, with Bruce Linton joining the board as Chairman and Billy Levy joining as Director.
BOCA RATON, FLORIDA / ACCESS Newswire / October 20, 2025 / Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (Nasdaq:GNLN) today announced the pricing and signing of a private investment in public equity (“PIPE”) transaction (“the Transaction”). The Transaction is being led by Polychain Capital with participation from a high-quality group of investors including Blockchain.com, Kraken, North Rock Digital, CitizenX, dao5 and more.
The Company intends to use the net proceeds of the Transaction to implement a digital asset treasury strategy, and acquire BERA, the native cryptocurrency of the Berachain blockchain. BERA will serve as the Company’s primary treasury reserve asset. BERA is the fee token of Berachain, the first Layer 1 blockchain powered by Proof of Liquidity to help businesses scale and power on-chain economies.
“I believe BERA’s key differentiation is its yield source – in contrast to historic PoS chains like Ethereum and Solana, BERA’s yield is fueled by the monetization of its block rewards. I think there’s untapped potential in Berachain’s institutional growth as a whole. The team has built, what I believe to be, one of the most recognizable brands amongst crypto natives to-date, which we believe can grow with exposure in traditional capital markets” said Ben Isenberg, incoming Chief Investment Officer, BeraStrategy.
“We’re excited to work with this talented and forward-thinking team on the development of its Treasury Strategy,” said Jonathan Ip, General Counsel, Berachain Foundation. “BeraStrategy represents a key step in Berachain’s broader engagement with capital markets and institutional participants. The team’s deep conviction in our ecosystem, combined with their experience across traditional finance, crypto markets, and retail communities, positions them perfectly to expand BERA’s reach and impact.”
Following closing, the Company’s management team is expected to add decades of experience across global capital markets and technology businesses, including from incoming director and Chairman Bruce Linton and incoming director Billy Levy. Billy Levy is a serial entrepreneur and capital markets executive with a history of building, scaling, and exiting companies across multiple industries, including co-founding Virgin Gaming in collaboration with Sir Richard Branson. Bruce Linton previously led Canopy Growth Corporation to a $15B market capitalization and has extensive experience in leading companies across communications and cleantech.
“We firmly believe that BERA is ushering in the next age of blockchain incentive structures. As a result, we believe it provides a compelling opportunity in the capital markets,” said Bruce Linton.
Transaction Overview
The Transaction consists of a $110 Million PIPE transaction for the purchase and sale of Greenlane’s Class A common stock, and/or pre-funded warrants to purchase shares of Class A common stock, at a purchase price of $3.84 per share and $3.83 per pre-funded warrant. Investors that intend to fund their purchase amount with locked and/or unlocked BERA in the offering will only be issued and sold pre-funded warrants. The PIPE is composed of approximately $50M of cash or cash equivalents, and approximately $60M of BERA tokens. The Transaction is expected to close on or about October 23, 2025, subject to the satisfaction of customary closing conditions.
Upon closing, the Company intends to use the net proceeds from the offering primarily to fund the acquisition of BERA through open market purchases and over-the-counter transactions for the establishment of the Company’s BERA treasury operations, as well as for working capital and general corporate purposes.
Trading & Next Steps
The Company’s common stock will continue to trade on the Nasdaq Capital Market (Nasdaq: GNLN) with the updated treasury strategy effective immediately following the closing of the Transaction. The Company will emphasize transparency and verification of holdings and strong engagement with the BERA ecosystem and community.
Greenlane will continue operating its distribution business. The company expects to provide regular updates, including on its BERA acquisitions, treasury performance and governance measures, as it looks to build the largest institutionally-managed BERA position in the public markets.
Advisors
Aegis Capital Corp., served as exclusive placement agent for the offering.
Kaufman & Canoles, P.C. is acting as counsel to Aegis Capital Corp. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Company. Paul Hastings LLP is acting as counsel to Polychain Capital LP.
About Berachain
Berachain (BERA) is the first blockchain powered by Proof of Liquidity, designed to help businesses scale and provide sustainable on-chain economies. Proof of Liquidity provides BERA with a staking yield derived from the revenues or ownership of profitable, revenue-generating companies building on the network. Berachain has raised $150M from leading digital asset investors including Brevan Howard, Framework Ventures, Polychain Capital, Samsung Next, Laser Digital by Nomura, Goldentree Asset Management, SBI VC Trade and more.
About Polychain Capital LP
Polychain Capital, founded in 2016 by Olaf Carlson-Wee, is a premier investor in cryptocurrency protocols and companies. The highly crypto-native firm utilizes a hands-on, participatory approach towards investments with the goal to accelerate the global adoption of crypto.
About Greenlane Holdings, Inc.
Founded in 2005, Greenlane is a premier global platform for the development and distribution of premium smoking accessories, vape devices, and lifestyle products to thousands of producers, processors, specialty retailers, smoke shops, convenience stores, and retail consumers. We operate as a powerful family of brands, third-party brand accelerator, and an omnichannel distribution platform.
We proudly offer our own diverse brand portfolio and our exclusively licensed Marley Natural and K.Haring branded products. We also offer a carefully curated set of third-party products through our direct sales channels and our proprietary, owned and operated e-commerce platforms which include Vapor.com, PuffItUp.com, HigherStandards.com, Wholesale.Greenlane.com and MarleyNaturalShop.com.
The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from the registration requirement of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder, and applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirement of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock and the shares of common stock underlying the pre-funded warrants. Any offering of the Company’s common stock under the resale registration statement will only be made by means of a prospectus. The securities have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
The information provided in this press release is intended for informational purposes only and does not constitute investment advice, endorsement, analysis, or recommendations with respect to any financial instruments, investments, or issuers. Investment in cryptocurrency and decentralized finance (DeFi) projects involves substantial risk, including the risk of complete loss of investment. This press release does not take into account the investment objectives, financial situation, or specific needs of any particular person and each individual is urged to consult their legal and financial advisors before making any investment decisions.
This press release contains statements that constitute “forward-looking statements” within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than historical facts and include, without limitation, statements regarding the potential for and amount of additional cash proceeds from warrant exercises, the anticipated closing date of the PIPE, use of proceeds from the announced PIPE, future announcements and priorities, expectations regarding management, market position, business strategies, future financial and operating performance, and other projections or statements of plans and objectives.
These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors-many of which are beyond the Company’s control-that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect actual results include, among others, the Company’s ability to execute its growth strategy; its ability to raise and deploy capital effectively; developments in technology and the competitive landscape; the market performance of BERA; and other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on March 21, 2025, and in other subsequent filings with the SEC. These filings are available at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Tax experts warn that relocating won’t stop the IRS from collecting on unpaid taxes – and could even make matters worse.
IRVINE, CALIFORNIA / ACCESS Newswire / October 29, 2025 / Some Americans burdened by tax debt believe that packing up and moving to another state might offer a way out. But according to experts at Clear Start Tax, changing your address does not make your federal tax debt disappear – and in some cases, it can complicate IRS collection efforts.
While state taxes vary, federal tax obligations remain unchanged no matter where a taxpayer resides. The Internal Revenue Service has broad authority to collect outstanding debts nationwide, including garnishing wages, levying bank accounts, or placing federal liens on property.
“Relocating doesn’t give you a clean slate with the IRS,” said a spokesperson for Clear Start Tax. “Tax debt follows you. The agency has nationwide reach and can enforce collection actions regardless of where you live.”
Many taxpayers also overlook that moving can actually extend the collection statute of limitations. Leaving the country or residing in a state with different administrative procedures may pause the clock on how long the IRS can legally pursue collection – giving the agency even more time to act.
“Trying to ‘outrun’ the IRS is a costly misconception,” the spokesperson added. “If anything, it gives the government more time to collect, not less. Taxpayers who relocate without resolving their debt often face bigger problems down the road.”
Tax professionals recommend that anyone considering a move should review their IRS Collection Statute Expiration Date (CSED), consult with a qualified tax specialist, and address their balance before relocating to avoid unexpected enforcement actions.
By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.
About Clear Start Tax
Clear Start Tax is a trusted national tax resolution firm that helps individuals and businesses navigate complex IRS and state tax issues. With a team of experienced tax professionals, the company provides strategic solutions for back taxes, liens, levies, and tax relief programs. Clear Start Tax has helped thousands of taxpayers regain financial stability and peace of mind.
The field hockey star uses the sam® sustained acoustic medicine device from ZetrOZ Systems to manage knee osteoarthritis, keep playing and prepare for future competitions.
TRUMBULL, CT / ACCESS Newswire / October 20, 2025 / Olympic athletes need the most advanced methods to perform at the highest level of sport and to recover from workouts and injuries. After competing in field hockey at the 2024 Paris Olympic Games, Ashley Hoffman turned to the sam® wearable ultrasound unit from ZetrOZ Systems to manage her knee osteoarthritis.
As the latest sam® brand ambassador, Hoffman is sharing how the wearable ultrasound device helps with her knee problems.
“I really like to use my sam® device, particularly after I train. I feel the heat and know that it is helping keep my knee calm so I can continue to train how I want to. I love that it is portable; sometimes I put it on for a 4-hour session and forget that it is even there,” Hoffman said.
“I’ve been through an ACL recovery, and now I’m managing this with my other knee, so if you aren’t ready to hang up your cleats either, it’s worth a try. I’ve had less pain after training, after using the device for only a few weeks,” she said.
Sustained acoustic medicine, invented by ZetrOZ Systems, is continuous, long-duration ultrasound treatment applied directly to the site of an injury. More than 30 clinical studies and 3.7 million patient treatments have validated the effectiveness of sustained acoustic medicine and the ZetrOZ Systems sam® wearable ultrasound devices in reducing pain, improving function and helping people return to sports and daily activities.
Hoffman began playing field hockey in second grade, which led to a college career at the University of North Carolina. In 2017, her Tar Heels lost by one goal in the national semifinals and vowed they wouldn’t lose again. The following season, the Tar Heels posted an undefeated 22-0 season and won the national championship. “The team that year was incredible,” she said. “We were so bonded and had each other’s backs, which made playing such a joy.”
Hoffman’s collegiate success and hard work landed her a spot on the U.S. Olympic team for the Paris 2024 Olympics. The team had to battle through the qualifying round against many higher-ranked opponents. “We were 2-1 down to Japan with six minutes to go in the fourth quarter and ended up winning 3-2,” Hoffman recalled. “I scored a corner flick, and Abby Tamer scored the game-winner on a corner rebound. It was euphoric. The whole of the tournament, though, the team was able to maintain an eerie calm confidence, I think, because we were just enjoying what we were doing so much.”
To keep playing and possibly prepare for another Olympics competition, Hoffman is relying on the sam® unit after training to manage the pain and swelling from her condition.
“For me, a non-invasive way of managing swelling and pain was crucial for me to consider what this next Olympic cycle might look like,” Hoffman said. “Athletes often have this need to do everything possible to make sure they can train and play, so having my own sam® device to include in my recovery routines gives me that confidence.”
ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices to deliver sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of 46 patents and is the exclusive manufacturer and developer of the sam® product line, designed to treat acute and chronic musculoskeletal conditions.
SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in a humanized animal model. The Company announces that NV-387 can now be made available for emergency use application in Measles patients to respond to the spreading Measles outbreaks.
Having a drug to treat patients has become of paramount importance, in view of the fact that the USA is about to return to an endemic playground for the Measles virus, with over 1,600 cases as of October 17, breaking a thirty-year-plus-long record this year1.
“We have already developed an effective drug to respond to the Measles virus outbreaks spreading all across the country,” said Anil R. Diwan, PhD, President.
“NV-387 can be used right away for emergency use in Measles cases,” said Krishna Menon, VMD, MRCS, PhD, Consulting Scientist (Non-Clinical), adding, “With my extensive experience with non-clinical development of several marketed drugs, I can definitely say that NV-387 has excellent activity and safety in treating Measles virus infection.”
Dr. Menon designed and conducted the humanized animal model studies for testing drugs against Measles virus infection. As such, he has hands-on experience with the effects of the drug NV-387. The data has provided compelling evidence that NV-387 is indeed highly effective in protecting the infected from the systemic effects of Measles infection.
“The drug is manufactured under GMP in the USA,” added Jayant Tatake, PhD, Vice President of the Company.
NV-387 has already completed Phase I clinical trial in healthy subjects with no reported adverse events.
The Company has previously reported that in a humanized animal model of lethal Measles infection, NV-387 treatment increased survival of animals to 17 days on average compared to only 7.4 days in untreated animals, an increase of 130%. There were no signs of toxicity from the drug NV-387. Additionally, dose-dependent increase in survival was observed. In contrast, Ribavirin, an unapproved drug that may be used off-label for severe Measles cases as per CDC guidance, is known to be highly toxic.
The Company intends to support any Physician’s Investigator Initiated New Drug Application (IIND) for emergency use of NV-387 for treatment of one or a few cases of Measles, as per FDA regulations. The Company requests physicians that would like to avail of this opportunity to contact us.
NV-387 is a revolutionary novel drug that defines a new mechanism of action, in that it attacks the virus particles and destroys them.
NV-387 is available as Oral Gummies, which dissolve slowly in the mouth; and do not require swallowing. Swallowing can be difficult for a patient in presence of a rash.
With Measles outbreaks spreading all across the country, the USA is expected to lose the Measles elimination status, and the virus would be considered endemic thereafter as it was before 2000. However, Measles is extremely contagious, and more than 95% population needs to be vaccinated to eliminate the disease. To complicate the matters, persons with weakened or otherwise affected immune systems do not benefit from vaccination because their immune system cannot mount response to the challenge.
Further, it has become clear in recent years that the Measles virus is drifting from the current vaccine strain (circa 1968) over the last fifty years, and there is evidence that some variants may have arisen that have greater resistance to the vaccine than in the past.
Thus a drug for combating this emerging infectious disease is important. Regulatory development of a drug specific for Measles is not cost-effective.
NV-387 can be readily developed for Measles through FDA licensure, because it is a multi-purpose, broad-spectrum antiviral. NV-387 is being developed to treat several different viral infections acquired by the respiratory route. The Company is working on regulatory development of NV-387 as a treatment for viral infections that include RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, the epidemic-threat MPox and the bio-terrorism threat, Smallpox.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.
PHILADELPHIA, PA / ACCESS Newswire / October 20, 2025 / Joseph V. Scorese, a nationally recognized Direct Private Lender and real estate finance expert, has officially joined Truly Investor Capital, a leading nationwide platform specializing in private and white-label lending programs.
This milestone coincides with two major achievements in Joseph’s career:
150 Episodes of The Creative BRRRR Strategies Podcast – one of the industry’s most trusted educational platforms for real estate investors and lenders.
10 Years of Real Estate Mastermind Strategies Events – a rapidly expanding multi-state networking series connecting investors across Pennsylvania, New Jersey, Delaware, Connecticut, and beyond.
“Joining Truly Investor Capital represents the next evolution in helping real estate investors scale smarter and faster through strategic lending partnerships,” said Joseph V. Scorese. “It’s about more than financing deals – it’s about building relationships and creating lasting opportunities.”
Through his partnership with Truly Investor Capital, Joseph continues to deliver Nationwide Direct Private Lending Solutions, including DSCR rental loans, fix-and-flip financing, bridge and construction loans, and white-label broker opportunities.
Nationwide Asset-Based Lending & White-Label Correspondent Program
We are a nationwide direct asset-based lender dedicated to empowering real estate investors with reliable, flexible, and fast funding solutions. Whether you’re building, buying, or refinancing, we help you close with confidence.
Core Loan Programs
Rental Loans (DSCR): 1-12 units | Up to $5M
Fix & Flip Loans: Competitive rates & rapid draws
Portfolio Rental Loans: Blanket options for multiple properties
The Deal Marks Commonwealth M&A’s Fifth Transaction in the Home Services Space
PHILADELPHIA, PA / ACCESS Newswire / October 20, 2025 / Commonwealth M&A, LLC, a premier full-service Merger & Acquisition advisory firm providing transactional and valuation services to small and medium-sized businesses, has announced the acquisition of its client, Oxford Plumbing & Heating, by Sila Services, a leading home services platform.
For more than 70 years, Oxford Plumbing & Heating has built its reputation as one of Chester County’s most trusted providers of residential and commercial plumbing and heating services. As a third-generation family-owned business, Oxford is known for its reliable service, deep community ties, and customer reach – making it one of the most respected names in the region’s home services market.
“It was important for us to partner with a team who respected the legacy our grandfather built starting in 1951 and could seamlessly and expertly guide us through every step of the transition,” said Ryan Edgington, former Owner and President of Oxford Plumbing and Heating. “Commonwealth M&A not only understood the plumbing and heating industry, but could easily grasp the uniqueness of a third-generation family business. We trusted them to advocate for what mattered most to us: our employees, our customers, and our reputation – and they truly delivered an outcome that honored us while securing the best future.”
Commonwealth M&A is dedicated to guiding business owners through one of the most important decisions of their lives. A company as rich in history and legacy as Oxford Plumbing & Heating perfectly exemplifies that mission. By recognizing Oxford’s past and positioning it for continued growth, the firm ensures that legacy businesses not only realize their value but are prepared to thrive for generations to come.
“Advising Oxford Plumbing & Heating was an honor for our team,” said Rick Calabrese, Co-Founder of Commonwealth M&A. “Multi-generational businesses are rare these days, and carry tremendous legacy. The Edgington family built a trusted name over decades, and we’re proud to have played a part in positioning Oxford for continued success under Sila Services.”
“The home services sector has been really hot in the M&A market this year, but having managed several other HVAC deals, we’ve learned that there are definitely nuances when it comes to positioning the seller and highlighting the value of the business. Oxford is such a legacy name in the Pennsylvania area, we really wanted to do them justice and our past experience allowed us to leverage the right conversations to secure a deal that was right for them and for the buyer,” said Joe Bergin, Co-Founder of Commonwealth M&A.
This transaction marks Commonwealth M&A’s fifth home services transaction and demonstrates the firm’s consistent ability to facilitate successful outcomes for owners and their teams in this space.
About Commonwealth M&A, LLC
Commonwealth M&A, LLC is a full-service Merger & Acquisition advisory firm providing transactional and valuation services to small and medium sized businesses. Commonwealth M&A offers a differentiated approach derived from the team’s diverse set of experiences. Our mission is to deliver personalized, high-quality service that exceeds expectations.
If you are a business owner looking to sell your company, Commonwealth M&A is here to help. Contact us today to learn more about our services and how we can assist you in achieving your goals. Visit us at https://commonwealthmna.com.
How Brands Use De-Positioning to Outthink and Outmaneuver Their Competition
NEW YORK CITY, NY / ACCESS Newswire / October 20, 2025 / Branding strategist and Fazer founder Todd Irwin announces the release of his debut book, De-Positioning: The Secret Brand Strategy for Creating Competitive Advantage, a groundbreaking framework that challenges decades of conventional marketing wisdom and exposes why differentiation no longer drives growth in today’s hypercompetitive markets.
For years, companies have been told to “differentiate,” meaning to stand out by being faster, cheaper, or better. In De-Positioning, Irwin argues that in oversaturated markets, companies can no longer win through strategies that emphasize “different.” Different isn’t enough. Irwin’s proprietary methodology reveals how the world’s most successful brands, such as Apple, Volvo, and Tesla, win by subtly redirecting the positions of competitors to strengthen their own.
“For years, I watched traditional positioning fail brands in the real world,” Irwin says. “De-Positioning was born out of the need for a strategy that actually works in today’s brutally competitive markets. It challenges the old playbook and shows how brands can dominate by turning customer pain into their greatest competitive weapon.”
Rooted in behavioral science and the Engel-Blackwell-Miniard model of consumer behavior, Irwin’s methodology turns decades of academic theory into a practical, repeatable system for winning market share. In accessible and engaging language, the book outlines six principles that define this approach, championing the customer, solving “hero” pain points, understanding competitor weaknesses, and building coherence and integration across every brand touchpoint.
The book has already drawn praise from industry legend Jon Bond, cofounder of the trailblazing agency Kirshenbaum Bond & Partners, whose work helped define modern advertising. Bond, who penned the book’s foreword, calls De-Positioning “a rare combination of strategic depth and real-world clarity” and credits Irwin with articulating what marketers have long felt but couldn’t name.
De-Positioning has also received early endorsements from some of the world’s foremost marketing thinkers beyond the advertising world. Erich Joachimsthaler, Ph.D., postdoctoral fellow at Harvard Business School, CEO of Vivaldi Group, and co-author of Brand Leadership, writes, “Irwin is a master brand strategist. He shows how brands, when viewed as mental real estate in consumers’ minds, deliver competitive advantage and enormous financial value for firms. Brilliant.”
With a mix of strategic insight, case studies, and actionable frameworks, De-Positioning offers business leaders a practical roadmap to redefine their markets and create lasting competitive advantage.
De-Positioning: The Secret Brand Strategy for Creating Competitive Advantage is available now for preorder on Amazon and Barnes & Noble.
About Todd Irwin Todd Irwin is the Founder and Chief Strategy Officer of Fazer, a brand strategy firm that helps companies dominate in hypercompetitive markets. Over three decades, he has led strategy for Fortune 500 companies as well as venture-backed disruptors funded by Sequoia, Andreessen Horowitz, and Google Ventures. Irwin pioneered the strategic methodology known as De-Positioning, a rigorous, customer-first approach that flips traditional branding on its head. His work has been featured in The New York Times, Forbes, and MIT Technology Review. De-Positioning distills his three decades of experience into a playbook for leaders who want to stop competing and start controlling their markets.
About Fazer Fazer is a new model, global brand strategy firm that helps companies outsmart, not outspend, their competitors. Its proprietary De-Positioning methodology builds brands around customer pain points-transforming competitive weaknesses into enduring advantage. Founded by veteran strategist Todd Irwin, Fazer combines the rigor of a consultancy with the creativity of a boutique. Its senior-only team partners with ambitious leaders at brands like Verizon, Bang & Olufsen, and SiriusXM to redefine categories and create brands that win by design, not by chance.
DALLAS, TX / ACCESS Newswire / October 20, 2025 / Adapti, Inc. (OTCID:ADTI), a company developing AI technology to integrate sports and influencer management, today announced that it has signed a Letter of Intent (LOI) to acquire Levelution Sports, a premier NIL representation agency specializing in compliance, brand partnerships, and athlete development.
The proposed acquisition underscores Adapti’s broader strategy to build a multi-sport, multi-discipline athlete management platform that combines traditional representation with cutting-edge digital and NIL capabilities. By integrating Levelution Sports into its platform, Adapti will provide its roster of athletes with expanded resources, expertise in NIL compliance, and access to new partnership opportunities.
“Signing this LOI with Levelution Sports is another important step in our growth strategy,” said Adam Nicosia, CEO of Adapti. “Kirk and his team have built a respected agency with deep NIL expertise, and we believe their work will be an incredible complement to our expanding sports and influencer management platform. Together, we can deliver even greater opportunities for athletes to succeed both on and off the field.”
“At Levelution Sports, our mission has always been to empower athletes with the tools and guidance needed to maximize their potential in the NIL era,” said Kirk Lee Noles, CEO of Levelution Sports. “Joining forces with Adapti will allow us to scale that mission, expand our impact, and provide unmatched opportunities for our clients. We’re excited about what this future holds.”
Transaction terms were not disclosed.
About Adapti
Adapti, Inc. (OTC: ADTI), leverages advanced AI technology to match products and brands with optimal influencers, using proprietary data analytics to drive superior marketing results. Adapti aims to build a global platform where data is an asset, efficiently paired with high-impact influencers.
In July 2025, Adapti acquired the Ballengee Group, a full-service sports agency representing Major League Baseball athletes. The Ballengee Group assists its clients with contract negotiations, marketing deals, public relations, and strategic partnerships. The Ballengee Group has guided world champions and global icons throughout their careers.
Adapti plans to roll out a suite of integrated services that blend traditional contract negotiation and endorsement deals with dynamic social media campaigns, which we anticipate will be powered by AdaptAI’s proprietary “data fingerprint” technology that the company is developing. This technology will utilize Large Language Models to quickly optimize and adapt to changes in the ever-evolving marketing landscape. This holistic approach is being designed to maximize engagement, drive higher ROI for brand partners, and ensure athletes capture every opportunity to grow their platforms.
About Levelution Sports
Levelution Sports is a NIL representation agency dedicated to helping athletes navigate the evolving landscape of Name, Image, and Likeness. With a focus on compliance, brand partnerships, and long-term career development, Levelution provides athletes with the tools and resources needed to excel in sports, business, and life. Learn more at www.levelutionsports.com.
